Paclitaxel Inhibits Synoviocyte Migration and Inflammatory Mediator Production in Rheumatoid Arthritis

Area of Science:

• Rheumatology
• Pharmacology
• Molecular Biology

Background:

• Activated fibroblast-like synoviocytes (FLSs) are key drivers in rheumatoid arthritis (RA) pathogenesis.
• Developing novel therapeutics to inhibit RA-FLS activation is crucial.

Purpose of the Study:

• To evaluate the therapeutic potential of paclitaxel (PTX) in inhibiting RA-FLS activation and progression.
• To elucidate the molecular mechanisms underlying PTX's effects on RA-FLS.

Main Methods:

• Utilized the RA-FLS cell line MH7A and a collagen-induced arthritis (CIA) mouse model.
• Assessed PTX's effects on FLS migration, gene expression (IL-6, IL-8, RANKL, IL-1β, MMP-8, MMP-9), and apoptosis.
• Investigated PTX's impact on MAPK and AKT/mTOR signaling pathways via Western blot analysis.

Main Results:

• PTX inhibited RA-FLS migration dose-dependently and reduced spontaneous and TNF-α-induced inflammatory gene expression.
• PTX did not significantly affect RA-FLS apoptosis.
• PTX suppressed TNF-α-induced phosphorylation of ERK1/2 and JNK (MAPK pathway) and activation of AKT, p70S6K, 4EBP1, and HIF-1α (AKT/mTOR pathway).
• PTX treatment alleviated synovitis and bone destruction in CIA mice.

Conclusions:

• PTX demonstrates efficacy in inhibiting RA-FLS migration and inflammatory mediator production.
• PTX exerts its effects by modulating the MAPK and AKT/mTOR signaling pathways.
• These findings support PTX as a potential therapeutic agent for rheumatoid arthritis.